null Luis Souhami, MD

Investigator, RI-MUHC, Glen site

Cancer Research Program

Professor, Gerald Bronfman Department of Oncology, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Radiation Oncology, MUHC



central nervous system tumors • gynecological malignancies • genito-urinary malignancies

Research Focus

My research focuses on the treatment of tumors involving the brain, the gynecology area and the urogenital area.

Selected Publications

Click on Pubmed to see my current publications list

  • Turgeon G-A, Souhami L, Cury FL, Faria SL, Duclos M, Sturgeon J, Kassouf W. Hypofractionated IMRT in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer. Int J Radiat Oncol Biol Phys 88:326-331, 2014. PMID: 24411604.

  • Patel N, Souhami L, Mansure JJ, Duclos M, Aprikian A, Faria S, David M, Cury FL. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. Brachytherapy 13:450-455, 2014. PMID: 25023396.

  • Owen S, Souhami L. The management of brain metastases in non-small cell lung cancer. Frontiers in Oncology 4:1-5, 2014. PMCID: PMC4164096.

  • Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, Cowan R, Kostashuk EC, Anderson J, Swanson G, Parmar MK, Hayter C, Jovic G, Hiltz A, Hetherington J, Sathya J, Barber JB, McKenzie M, El-Sharkawi S, Souhami L, Hardman PD, Chen BE, Warde P. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol. 2015 Feb 17. pii: JCO.2014.57.7510. [Epub ahead of print]. PMID: 25691677.

  • Viswanathan AN, Moughan J, Miller BE, Xiao Y, Jhingran A, Portelance L, Bosch WR, Matulonis UA, Horowitz NS, Mannel RS, Souhami L, Erickson BA, Winter KA, Small W Jr, Gaffney DK. NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Apr 6. doi: 10.1002/cncr.29337. [Epub ahead of print] PMID: 25847373.